approved glp-1 agonists GLP-1: Genetic Variants Related to RA Medications GLP-1 receptor agonists and next-generation

Bimagrumab Bimagrumab is a human monoclonal antibody that stimulates skeletal muscle growth by blocking the activin type II receptor (ActRII) and it is administered as a four-weekly intravenous infusion [96]

(Source: In February 2026 , Novo Nordisk announced the broad American availability of the Wegovy pill, introducing the first and only oral GLP-1 receptor agonist for adult weight loss

Tirzepatide exerts its therapeutic effects through dual agonism of two key incretin receptors: the GIPR and the GLP-1R

The most common side effects for GLP-1 RAs were nausea, vomiting, diarrhea and constipation

Morvan, F

Technological advancements in delivery systems and oral formulations are creating disruptions and trends, forcing competitors to adapt their product offerings